Drug intelligence / Profile preview

KPMF-8

Development stage: Unknown
Lead developer: Tokiwa Phytochemical Company
Modality: Small Molecules

Overview

KPMF-8 is a **small-molecule polymethoxyflavone** derived from *Kaempferia parviflora* and also synthesized from quercetin. It has been described as a **sirtuin-activating compound** that directly interacts with and activates **SIRT1**, with reported activity greater than resveratrol in experimental systems. The compound has been associated with research programs from **Tokiwa Phytochemical** and the **University of Tokyo**, and it has been identified as an active constituent of the proprietary *Kaempferia parviflora* extract Sirtmax. Publicly available context suggests a preclinical positioning around aging biology and age-related disorders rather than a clinically established therapeutic product.

Other names: quercetin 3,5,7,3′,4′-pentamethyl ether

Targets

SIRT1 (NAD-dependent protein deacetylase sirtuin-1)

Beyond the preview

Go deeper on KPMF-8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KPMF-8.

Explore the full profile